
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

**Current Report Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) March 4, 2009

PRESSURE BIOSCIENCES, INC.

(Exact Name of Registrant as Specified in its Charter)

MASSACHUSETTS

(State or Other Jurisdiction of Incorporation)

0-21615

(Commission File Number)

04-2652826

(IRS Employer Identification No.)

14 Norfolk Avenue, South Easton, MA

(Address of Principal Executive Offices)

02375

(Zip Code)

(508) 230-1828

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 2.02 Results of Operations and Financial Condition

On March 4, 2009, the Company issued a press release announcing its financial results for the quarter ended December 31, 2008. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference.

Limitation on Incorporation by Reference. The information furnished in this Item 2.02 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

Cautionary Note Regarding Forward-Looking Statements. Except for historical information contained in the press release attached as an exhibit hereto, the press release contains forward-looking statements which involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements. Please refer to the cautionary note in the press release regarding these forward-looking statements.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit Number Exhibit Description

99.1	Press release dated March 4, 2009 of Pressure BioSciences, Inc. announcing its financial results for the quarter ended December 31, 2008.
------	---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: March 4, 2009

PRESSURE BIOSCIENCES, INC.

By: /s/ Richard T. Schumacher
Richard T. Schumacher
President and Chief Executive Officer

EXHIBIT INDEX

Exhibit Number	Exhibit Description
-----------------------	----------------------------

99.1	Press release dated March 4, 2009 of Pressure BioSciences, Inc. announcing its financial results for the quarter ended December 31, 2008.
------	---

Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008

SOUTH EASTON, Mass., March 4 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO) ("PBI" or the "Company") today announced that total revenue for the fourth quarter of 2008 was \$334,041 compared to \$174,071 for the comparable period in 2007, a 92% increase. Revenue from the sale of PCT products and services was \$233,256 for the three months ended December 31, 2008 compared to \$118,703 for the same period in 2007, a 97% increase. During the fourth quarter of 2008, the Company completed the installation of ten Barocycler instruments, as compared to seven during the same period of 2007. Eight of the ten were domestic installations and two were international sales, compared to three domestic installations and four international sales for the same quarter in 2007.

Operating loss for the fourth quarter of 2008 was \$900,100 compared to \$1,297,975 for the same period in 2007, a decrease of \$(397,875) or 30%. This decrease in operating loss was primarily related to the Company's restructuring program announced on December 1, 2008, the cost containment initiatives that the Company instituted during the second and third quarters of 2008, and the record revenues of the 2008 fourth quarter. The Company currently expects its operating loss to continue to decrease to an average of less than \$600,000 per quarter during 2009.

As the Company is completing its annual financial reporting and auditing process, the revenue and operating numbers mentioned in this release are unaudited.

Richard T. Schumacher, President and CEO of Pressure BioSciences, Inc. said: "The fourth quarter of 2008 was extremely difficult for PBI. Faced with a very tough economic climate and decreasing cash, we made the difficult decision to significantly restructure the Company. Changes related to the restructuring program included a reduction in force from twenty to twelve employees, the implementation of significant cost reduction initiatives, and a realignment of our corporate strategy to focus on key products and application areas with the greatest likelihood for success."

Mr. Schumacher continued: "Amidst the upheaval and uncertainty resulting from these changes, we were still able to complete a license agreement with Battelle Memorial Institute; enter into a collaboration agreement with the J. Craig Venter Institute; sign an initial distribution agreement with Omni International; make significant progress towards the planned Q3 2009 release of our PCT-enhanced Protein Digestion System, including the next generation small and variable volume consumable processing containers; release a new product called the PCT Shredder; and make measurable progress on our equity financing efforts (completed on February 12, 2009). Concomitantly, we were also able to achieve record revenue while significantly reducing our operating loss. All stakeholders of the Company should be extremely proud of the team that we have at PBI, just as I am."

As previously announced, the Company completed a \$1.8 million equity financing on February 12, 2009. In connection with the financing, investors purchased units, with each unit consisting of (i) one share of Series A Convertible Preferred Stock (the "Series A Preferred Stock"), (ii) a warrant to purchase 10 shares of Common Stock at an exercise price equal to \$2.00 per share with a term expiring 30 months after the date of the closing of the financing, and (iii) a warrant to purchase, at the investor's election to be made within 7 days of the closing, either 10 shares of Common Stock at an exercise price equal to \$1.25 per share with a term expiring 15 months after the closing (the "15-Month Common Stock Warrants") or one share of Series A Preferred Stock at an exercise price equal to \$12.50 per share with a term expiring 15 months after the closing (the "15-Month Preferred Stock Warrants"). All 35 investors elected the 15-Month Preferred Stock Warrants. Since the Company had agreed to register the shares of Common Stock underlying the 15-Month Common Stock Warrants, as a result of the investors' elections, the Company will not be registering shares of Common Stock underlying the 15-Month Common Stock Warrants.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including genomic and proteomic sample preparation, pathogen inactivation, the control of chemical (primarily enzymatic) reactions, immunodiagnosics, and protein purification. PBI currently focuses its efforts in the development and sale of PCT-enhanced enzymatic digestion products designed specifically for the mass spectrometry marketplace, as well as sample preparation products for biomarker discovery, soil and plant biology, forensics, and counter-bioterror applications.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements include statements regarding the sufficiency of the Company's cash resources to fund its planned operations through the second quarter of 2010, the Company's expectation that its operating loss will continue to decrease to an average of less than \$600,000 per quarter in 2009, the Company's ability to achieve its business goals, the effect of the Company's decision to focus primarily on the application of PCT-enhanced protein digestion for the mass spectrometry market and the advantages of PCT in this market, and the use of PCT in biomarker discovery, soil and plant biology, counter-bioterror, and tissue pathology applications. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: possible difficulties or delays in the implementation of the Company's strategies that may adversely affect the Company's continued commercialization of its PCT System; changes in customer's needs and technological innovations; the Company's sales force may not be successful in selling the Company's PCT product line because scientists may not perceive the advantages of PCT over other sample preparation methods, particularly in the mass spectrometry market; scientists may not be able to duplicate the results achieved at particular laboratories having already used PCT; and if actual operating costs are higher than anticipated, or revenues from product sales are less than anticipated, the Company will need additional capital sooner than the second quarter of 2010. Further, the Company expects that it will need additional capital to fund its continuing operations beyond the second quarter of 2010. Additional risks and uncertainties that could cause actual results to differ materially from those indicated by these forward-looking statements are discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website <http://www.pressurebiosciences.com>

Investor Contacts:

Richard T. Schumacher, President & CEO

R. Wayne Fritzsche, Chairman

Pressure BioSciences, Inc.

(508) 230-1828 (T)

Consolidated Balance Sheets
(Unaudited)

<u>ASSETS</u>	December 31,	
	<u>2008</u>	<u>2007</u>
CURRENT ASSETS		
Cash and cash equivalents	\$ 918,208	\$5,424,486
Accounts receivable	209,117	118,471
Inventories	571,831	172,548
Deposits	382,236	553,483
Prepaid income taxes	6,600	56,863
Income tax receivable	-	249,541
Prepaid expenses and other current assets	235,111	94,783
Total current assets	<u>2,323,103</u>	<u>6,670,175</u>
PROPERTY AND EQUIPMENT, NET	<u>252,249</u>	<u>257,797</u>
OTHER ASSETS		
Intangible assets, net	279,658	328,290
TOTAL ASSETS	<u><u>\$2,855,010</u></u>	<u><u>\$7,256,262</u></u>
<u>LIABILITIES AND STOCKHOLDERS' EQUITY</u>		
CURRENT LIABILITIES		
Accounts payable	\$ 263,486	\$ 152,729
Accrued employee compensation	161,374	377,190
Accrued professional fees and other expenses	278,982	191,359
Deferred revenue	16,705	15,075
Total current liabilities	<u>720,547</u>	<u>736,353</u>
LONG TERM LIABILITIES		
Deferred revenue	10,821	6,767
TOTAL LIABILITIES	<u>731,368</u>	<u>743,120</u>
COMMITMENTS AND CONTINGENCIES		
STOCKHOLDERS' EQUITY		
Preferred stock; 1,000,000 shares authorized; 0 outstanding	-	-
Common stock, \$.01 par value; 20,000,000 shares authorized; 2,195,283 shares issued and outstanding on December 31, 2008 and 2,192,175 shares issued and outstanding on December 31, 2007	21,953	21,922
Additional paid-in capital	6,803,530	6,284,616
Retained (deficit) earnings		(4,701,841) 206,604
Total stockholders' equity		<u>2,123,642</u> <u>6,513,142</u>
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY		<u><u>\$ 2,855,010</u></u> <u><u>\$ 7,256,262</u></u>

Consolidated Statements of
Operations
(Unaudited)

For the Three Months
Ended
December 31,

	2008	2007
--	------	------

REVENUE:

PCT Products, services, other	\$ 233,256	\$ 118,703
Grant revenue	100,785	55,368
Total revenue	<u>334,041</u>	<u>174,071</u>

COSTS AND EXPENSES:

Cost of PCT products and services	133,601	77,492
Research and development	481,435	503,879
Selling and marketing	302,443	399,718
General and administrative	<u>316,662</u>	<u>490,957</u>
Total operating costs and expenses	<u>1,234,141</u>	<u>1,472,046</u>
Operating loss	(900,100)	(1,297,975)

OTHER INCOME:

Interest income	1,616	58,784
Total other income	1,616	58,784
Loss before income taxes	(898,484)	(1,239,191)
Income tax benefit	-	266,675
Net loss	<u>\$ (898,484)</u>	<u>\$ (972,516)</u>

Loss per share - basic and diluted	\$ (0.41)	\$ (0.46)
------------------------------------	-----------	-----------

Weighted average number of
shares used

to calculate net loss per share		
- basic		
and diluted	2,195,283	2,118,354

CONTACT: Investors, Richard T. Schumacher, President & CEO, R. Wayne Fritzsche, Chairman, both of Pressure BioSciences, Inc., +1-508-230-1828